Navigation Links
ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
Date:12/17/2013

BREDA, The Netherlands and GHENT, Belgium, December 17, 2013 /PRNewswire/ --

Dose confirmed for Phase Ib safety and efficacy expansion study

arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favourable safety profile and a dose has been selected to advance into the Phase Ib safety and efficacy expansion cohorts, which will start early in 2014 and are expected to report top-line results approximately 12 months later.

ARGX-110 is a first-in-class monoclonal antibody potently blocking CD70 induced tumor proliferation and tumor escape from immune surveillance. In addition, the POTELLIGENT®-enhanced antibody-dependent cellular cytotoxicity (ADCC) of ARGX-110 enables selective destruction of CD70-positive tumor cells. CD70 is overexpressed in the majority of cancer patients tested to date. Expectations of a favourable therapeutic index stem from its virtual absence in healthy tissues.

In the study, 19 patients with CD70-positive cancer were treated with escalating doses of ARGX-110, up to 10 mg/kg. The results show predictable pharmacokinetics across the dose range. No dose-limiting toxicity was identified. For Ahmad Awada, MD PhD, principal investigator of the study at the Jules Bordet Institute (Brussels, Belgium), "these results, at the clinical and immunological levels, open the door to study further the antibody as a single agent and in combination trials with small molecules and other immune checkpoint inhibitors."

Based on these data, arGEN-X will begin enrolment to hematology and solid tumor safety and efficacy expansion cohorts early in 2014 and report top-line r
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
2. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
3. Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
4. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
5. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
6. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
7. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
8. FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
9. Increasing Use of Allergans Botox and the Launch of Novel Nontriptan Products Will Be Key Drivers of Migraine Market Growth Through 2022
10. Novel Molecular Assay for Patient Screening Detects S. aureus and Newly Emerging MRSA Strains Available in the United States
11. Unilife Announces Clinical Supply Agreement for Delivery of a Novel Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Virginia , 11. Juli 2014 ... von Kameras für die molekulare Bildgebung, ... hat heute die CE-Zulassung für sein ... CE-Zeichen kann Dilon das Produkt jetzt ... auf den Großteil der europäischen Länder ...
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... MESA, Ariz., Dec. 6, 2011   Ulthera ... device company pioneering aesthetic and medical applications ... today announced that it has named Greg ... newly created position at Ulthera. ...
... Industries, Inc. (OTC.PK:PDMI) announced that it is continuing to move ... the limited working capital and market concerns it has had ... the mettle of Paradigm, its shareholders and remaining loyal employees. ... close, Paradigm remains hopeful it will see the DTC "chill" ...
Cached Medicine Technology:Ulthera Appoints Greg Waller as Chief Financial Officer 2Paradigm Business Update as of November 30, 2011 2
(Date:7/13/2014)... decreased ability to identify odors might indicate the ... examinations of the eye could indicate the build-up ... the brain, according to the results of four ... International Conference 2014 (AAIC 2014) in Copenhagen. , ... to identify odors was significantly associated with loss ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
(Date:7/13/2014)... 2014 Celebrity fitness trainer and former ... promotional partnership with Aqua Health Labs for their flagship ... supplement . The collaboration was recently announced live on ... trainer , actor, model, and a two time World ... celebrities, he has prepared stars including Demi Moore, Hilary ...
(Date:7/13/2014)... Illinois (PRWEB) July 13, 2014 Hope Palliative ... a monthly grief support group at the Tamarack Senior Living ... be held at 10:30 A.M. on the 3rd Wednesdays of ... 16th, 2014 at the Tamarack Community located at 55 S. ... all bereaved individuals and there is no cost for the ...
(Date:7/13/2014)... 2014 According to The Peripheral Neuropathy ... comprehensive program that teaches people how to deal with ... without medications. This program also provides people with safe ... neuropathy , including numbness, prickling, burning, and intense stabbing ... this home treatment program can help people eliminate some ...
Breaking Medicine News(10 mins):Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3
... Brody, Ph.D., assistant professor, Department of Surgery at Jefferson ... a 2010 Pancreatic Cancer Action Network American Association ... of Skip Viragh. This two-year grant awards $200,000 ... in pancreatic cancer. He will receive recognition for ...
... ... Action For Healthy Kids , was honored to be one of only 10 ... "Let,s Move" initiative to end childhood obesity in a generation. Flis was ... from D.C. and taking this opportunity to launch a Call to Action ...
... Douglas Smith, ... Officer; calls Consult A Doctor “the next evolution in medical care delivery, increasing access and ... Miami, FL ... Smith, board-certified family practice physician and pioneer of retail medical clinics, has joined as its ...
... ... Otology and Neurotology a “Letter to the Editor” documenting the improvement for memory loss ... focuses on two recent cases that were referred to Dr. Lippy, following stapedectomy surgery ... ...
... ... Music Announce April 13 Release , ... Los Angeles (PRWEB) April 14, 2010 -- LML Music announces the April ... the National Multiple Sclerosis Society. ,in my room, was conceived and produced by LML recording ...
... ... mobile networks will rise to almost $1.9 billion globally by 2014, with heart based monitoring ... ... According to Juniper Research, revenues from remote patient monitoring using mobile networks will rise to ...
Cached Medicine News:Health News:Jefferson researcher receives 2010 Pancreatic Cancer Action Network-AACR Career Development Award 2Health News:Mom Returns From D.C. Determined To Take On Childhood Obesity With A Call To Action For Parents 2Health News:Mom Returns From D.C. Determined To Take On Childhood Obesity With A Call To Action For Parents 3Health News:Consult A Doctor, Inc. Names Retail Clinic Pioneer, Douglas Smith, M.D. as Chief Medical Officer 2Health News:Consult A Doctor, Inc. Names Retail Clinic Pioneer, Douglas Smith, M.D. as Chief Medical Officer 3Health News:New Study Identifies Cause of Severe Disequilibrium and Significant Memory Loss Following Stapedectomy Surgery 2Health News:Peter Bradley Adams, Victoria Shaw, Many Distinguished Colleagues Ally To Benefit National MS Society With CD Release: In My Room 2Health News:Peter Bradley Adams, Victoria Shaw, Many Distinguished Colleagues Ally To Benefit National MS Society With CD Release: In My Room 3Health News:Peter Bradley Adams, Victoria Shaw, Many Distinguished Colleagues Ally To Benefit National MS Society With CD Release: In My Room 4Health News:Revenues from Mobile Health Monitoring to Reach $1.9 Billion Globally by 2014 Says Juniper Research 2Health News:Revenues from Mobile Health Monitoring to Reach $1.9 Billion Globally by 2014 Says Juniper Research 3
... 220XiIII quickly prints labels up ... 10 ips. It is ideal ... as printing chemical drum labels, ... industry labels, banner-sized labels and ...
... bedside Transfusion Verification System, is used ... patient receives the specific unit(s) of ... for them. It has the additional ... through their institution's policy and procedure ...
... helps ensure a safe care environment by automatically ... the unit dose level. The automated process and ... location and handling of all items, including vials, ... and more. This saves valuable time for pharmacy ...
... The Transfusion Safety Management system ensures ... products and care. , BloodTrack SafeTx uses ... the patient from sample collection to transfusion. ... transfused and reduces the need for bedside ...
Medicine Products: